Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (1933)	4/24/2010 4:32:45 AM
From: bob zagorin	Respond to of 1972

from vical web site.. AnGes MG In 2005, we granted an exclusive worldwide license to AnGes for use of our core DNA delivery technology in the development and commercialization of DNA-based products encoding Hepatocyte Growth Factor (HGF) for cardiovascular applications. AnGes is developing DNA-based delivery of HGF for indications related to PAD and ischemic heart disease, or IHD, which affects blood supply to the heart muscle. AnGes initiated Phase 2 trials in the United States and Phase 3 trials in Japan in 2003 and 2004, respectively, with DNA-based HGF for PAD. AnGes also initiated Phase 1 trials in the United States for IHD in 2004. AnGes has partnered with Daiichi Pharmaceutical Co., Ltd. for worldwide development and commercialization of DNA-based HGF for PAD and IHD. AnGes stopped its Phase 3 trial in June 2007 after an interim analysis on the first 41 patients showed that the primary efficacy endpoint in the trial had been achieved with statistical significance and that there were no major safety concerns related to treatment. On the basis of these data, AnGes is preparing to file for marketing approval in Japan. In May 2006, Vical and AnGes entered into a collaborative agreement for Vical's Allovectin-7® cancer immunotherapeutic. Under the agreement, AnGes will provide up to $100 million in ongoing clinical trial funding and future sales-based milestones as Allovectin-7® is successfully commercialized. Vical retains exclusive marketing rights for Allovectin-7® in the United States and the rest of the world outside of specified Asian countries, for which AnGes has exclusive rights. We announced in October 2008 that AnGes has signed a non-binding letter of intent with us indicating its mutual interest to license the development and marketing rights for our pandemic influenza DNA vaccines in Japan. AnGes plans to conduct due diligence on the pandemic influenza DNA vaccines, and both parties intend to negotiate terms and conditions potentially leading to a license. For program status, see the Product Development table.